Thursday, July 9, 2026 — Field Note
A deeper look at one story shaping medical device and health tech.
FIELD NOTE
The Fine Print on the Next Five Years
The medical device industry got its first look this week at the contract it will operate under through 2032. On Tuesday, the FDA posted the draft MDUFA VI commitment letter — the 36-page product of nearly a year of negotiations between the agency, AdvaMed, and the Medical Device Manufacturers Association over what industry user fees will buy in the sixth iteration of the device user fee program. The Federal Register notice followed Wednesday, opening a comment docket that closes July 29.
On paper, industry got much of what it asked for. The letter commits the agency to a new fast lane for pre-submission questions — written responses within 45 calendar days for focused follow-ups, launching by the end of 2027. De novo applicants would get a structured introduction meeting with reviewers inside the first 30 days of review. Major deficiency letters, a longstanding industry complaint, would require supervisory sign-off and a complete review before issuance. The TAP pilot graduates into a permanent program with hard metrics attached, including facilitated CMS engagement for devices that need new coverage determinations. And 510(k) decision targets start at an average of 128 calendar days for fiscal 2028 submissions, stepping down to 112 days by 2032.
The most quietly radical item is an international harmonization pilot slated for the end of fiscal 2028: a device submitted simultaneously to the FDA and at least two other regulatory authorities could get a coordinated review, with the agency leveraging elements of its counterparts’ assessments. The FDA retains final authority, and reliance is limited to an “abridged approach” — but an agency that has spent decades positioning itself as the global gold standard is now formalizing a mechanism to lean on other regulators’ work. That is a meaningful philosophical concession to resource reality.
Which is the tension running through the entire document. Every performance goal in the letter carries a conditional clause — the targets hold, the FDA writes, “provided that the total funding of the device review program adheres to the assumptions” underlying the agreement. That hedge is doing heavy lifting. This letter arrives at an agency that cut more than 3,000 roles last year and is now trying to hire 2,000, and it lands one week after BTIG data showed average PMA approval times reaching nearly 599 days in the first half — up from roughly 402 a year earlier. The agency is committing to move faster over the next five years at the precise moment its measured performance is moving in the other direction.
AdvaMed CEO Scott Whitaker welcomed the draft, framing it as delivering the stability and predictability innovators need. That’s the right corporate posture, and it’s also the industry’s real stake here: for companies planning submissions into 2028 and beyond, these targets are the planning assumptions that capital runways, launch calendars, and hiring plans get built on. A 128-day 510(k) average and a 45-day pre-sub lane are not abstractions — they’re inputs to every regulatory-timeline slide in every board deck for the next half decade.
The path from here is fixed: a public hybrid meeting on August 5, a final commitment letter to Congress by January 15, 2027, and enactment required by September 30, 2027, when MDUFA V expires. The window for the industry to shape the terms — or flag where the assumptions look shaky — is the next three weeks. After that, the fine print becomes the contract.
SPONSORED BY RŌG HEALTH
Where does your commercialization actually stand?
Two minutes to find out.
Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.
Want to put your brand in front of 35,000+ medical device and med tech leaders each week? Contact us to learn more about advertising opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.